6-K ·Filed May 28, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001575872-26-000370
Notable filing: 6-K
Actionable Insight • Neutral

Routine compliance filing with no trading implications. Monitor upcoming quarterly results for fundamental business performance indicators.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RDY ▼ -9.91% at T+60d
NEUTRAL call ✗ call lost -9.91% · α vs SPY -11.65% · entry $13.52 → $12.18
Entry anchored
May 28, 01:09 PM ET
via exchange tick
T+1d
+0.81%
call +0.81% · α +0.57%
$13.63
settled 4mo ago
T+5d
-3.70%
call -3.70% · α -3.65%
$13.02
settled 4mo ago
T+20d
+13.76%
call +13.76% · α +16.90%
$15.38
settled 3mo ago
T+60d
-9.91%
call -9.91% · α -11.65%
$12.18
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed its annual Secretarial Compliance Report for FY ended March 31, 2026, certifying compliance with SEBI listing regulations, insider trading rules, and corporate governance standards. The report confirms no material non-compliances, no regulatory actions taken against the company, and no resignation of statutory auditors during the period.

Key Facts

  • Annual Secretarial Compliance Report for FY ended March 31, 2026 filed on May 28, 2026
  • No non-compliances reported across all SEBI regulations examined
  • No actions taken by SEBI or stock exchanges against the company, promoters, directors, or subsidiaries
  • No resignation of statutory auditors from the listed entity or material subsidiaries during the review period
  • All applicable policies under SEBI regulations adopted and timely updated
  • Board performance evaluation conducted as prescribed
  • Related party transactions received prior Audit Committee approval

Financial Impact

No financial magnitude — this is a governance compliance certification with no monetary impact

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000370
Document: 0001575872-26-000370-index.html0001575872-26-000370
Document: 0001575872-26-000370.txt0001575872-26-000370
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access